Publications by authors named "Reiner Frey"

Claim this Profile
P
Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults.
Edwin DeJesus, Soundos Saleh, Sue Cheng, Dorina van der Mey, Corina Becker, Reiner Frey

Pulm Circ· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat.
Reiner Frey, Corina Becker, Soundos Saleh, Sigrun Unger, Dorina van der Mey

Clin Pharmacokinet· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications : Bamberg, Germany. 23-25 June, 2017.
G. Todd Milne, , Peter Sandner, Kathleen A. Lincoln, Paul C. Harrison, Reiner Frey

BMC Pharmacol Toxicol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Nicholas S Hill, Franck F Rahaghi, Namita Sood, Reiner Frey, Hossein-Ardeschir Ghofrani

Respir Med· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction : Study protocol for a randomized controlled trial.
Julia Mascherbauer, Ekkehard Grünig, Michael Halank, Wolfgang Hohenforst-Schmidt, Andreas A Kammerlander, Reiner Frey

Wien Klin Wochenschr· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
Xia Zhao, Zining Wang, Yukun Wang, Hong Zhang, Hartmut Blode, Reiner Frey

Clin Pharmacokinet· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality.
Corina Becker, Reiner Frey, Christiane Hesse, Sigrun Unger, Michael Reber

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
Reiner Frey, Corina Becker, Sigrun Unger, Anja Schmidt, Georg Wensing

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Riociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study.
Reiner Frey, Michael Reber, Jörn Krätzschmar, Sigrun Unger, Wolfgang Mück

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of omeprazole and aluminum hydroxide/magnesium hydroxide on riociguat absorption.
Corina Becker, Reiner Frey, Sigrun Unger, Ulrike Artmeier-Brandt, Gerrit Weimann

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic interaction of riociguat with ketoconazole, clarithromycin, and midazolam.
Corina Becker, Reiner Frey, Sigrun Unger, Dirk Thomas, Michael Reber

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
Reiner Frey, Corina Becker, Sigrun Unger, Anja Schmidt, Georg Wensing

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).
Reiner Frey, Soundos Saleh, Corina Becker, Wolfgang Mück

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food.
Soundos Saleh, Reiner Frey, Corina Becker, Sigrun Unger, Georg Wensing

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of single-dose riociguat in patients with renal or hepatic impairment.
Soundos Saleh, Corina Becker, Reiner Frey, Wolfgang Mück

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and the pharmacokinetic/pharmacodynamic relationship of riociguat in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
Soundos Saleh, Corina Becker, Reiner Frey, Wolfgang Mück

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic interaction study between riociguat and the combined oral contraceptives levonorgestrel and ethinylestradiol in healthy postmenopausal women.
Reiner Frey, Sigrun Unger, Dorina van der Mey, Corina Becker, Soundos Saleh

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
Stephan Rosenkranz, Hossein-Ardeschir Ghofrani, Maurice Beghetti, Dunbar Ivy, Reiner Frey

Heart· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease.
Hossein A Ghofrani, Gerd Staehler, Ekkehard Grünig, Michael Halank, Veselin Mitrovic, Reiner Frey

Pulm Circ· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study.
Diana Bonderman, Ingrid Pretsch, Regina Steringer-Mascherbauer, Pavel Jansa, Stephan Rosenkranz, Reiner Frey

Chest· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema.
Norbert Weissmann, Borja Lobo, Alexandra Pichl, Nirmal Parajuli, Michael Seimetz, Reiner Frey

Am J Respir Crit Care Med· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of the soluble guanylate cyclase activator cinaciguat in individuals with hepatic impairment.
Reiner Frey, Christian Scheerans, Martin Blunck, Wolfgang Mück, Mark Jean Gnoth

J Clin Pharmacol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the effects of renal impairment on the pharmacokinetics of the soluble guanylate cyclase activator cinaciguat after a single intravenous dose.
John T Lettieri, Christian Scheerans, Martin Blunck, Arthur L Mazzu, Reiner Frey

J Clin Pharmacol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design.
Stefano Ghio, Diana Bonderman, Stephan B Felix, Hossein A Ghofrani, Evangelos D Michelakis, Reiner Frey

Eur J Heart Fail· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study.
Reiner Frey, Wolfgang Mück, Nina Kirschbaum, Jörn Krätzschmar, Gerrit Weimann

J Clin Pharmacol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis